기저치를 가진 생물학적 동등성 평가의 통계적 고찰: 내인성 제제사례연구
Statistical Considerations in Assessing Bioequivalence with Baselines: A Case Study of Endogenous Drugs
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To assess bioequivalence between two endogenous drugs in 2×2 crossover trial with baseline measurements. Methods: Two statistical methods are applied to assess bioequivalence between two endogenous drugs in 2×2 crossover trials. The first method is based on the current regulatory guideline published by Ministry of Food and Drug Safety (MFDS), which is based on the difference between baseline measurements and responses. The second method is more general approach, so-called general linear model method, which is defined the baseline measurements as covariates. Results: The first method based on current guideline shows that two drugs are not bioequivalent; however, the second method by general linear model shows that two drugs are bioequivalent. When the baselines of the subjects are expected to be highly variable, general linear model approach is more suitable to assess the bioequivalence by adjusting high subjects’ variations. Conclusions: General linear model with covariates should be considered in assessing bioequivalence of endogenous substances when highly subject variations of baseline measurements are expected.
Abstract
Objectives: To assess bioequivalence between two endogenous drugs in 2×2 crossover trial with baseline measurements. Methods: Two statistical methods are applied to assess bioequivalence between two endogenous drugs in 2×2 crossover trials. The first method is based on the current regulatory guideline published by Ministry of Food and Drug Safety (MFDS), which is based on the difference between baseline measurements and responses. The second method is more general approach, so-called general linear model method, which is defined the baseline measurements as covariates. Results: The first method based on current guideline shows that two drugs are not bioequivalent; however, the second method by general linear model shows that two drugs are bioequivalent. When the baselines of the subjects are expected to be highly variable, general linear model approach is more suitable to assess the bioequivalence by adjusting high subjects’ variations. Conclusions: General linear model with covariates should be considered in assessing bioequivalence of endogenous substances when highly subject variations of baseline measurements are expected.
참고문헌 (10)
- Ministry of Food and Drug Safety, "Standard on pharmaceutical equivalence study", Ministry of Food and Drug Safety, ~ (2017)
- Park S, "Statistical methods for bioequivalence trials" (2014), Freedom Academy
- Ministry of Food and Drug Safety, "General considerations for bioequivalence studies" (2014), Ministry of Food and Drug Safety
- US Food and Drug Administration, "Draft guidance for industry: bioequivalence studies with pharmacokinetics endpoints for drugs submitted under an ANDA" (2013), US Food and Drug Administration
- Marzo A, "Bioequivalence of endogenous substances facing homeostatic equilibria: an example with potassium", Pharmacol Res, 42(6), pp.523~525 (2000)[DOI]
- Kenward MG, "The analysis of data from 2<TEX>$\times$<", TEX>2 cross-over trials with baseline measurements, 1987, pp.6(8), 911~926
- 정규진, "공변량을 고려한 2×2 교차설계법에서 평균 생물학적 동등성 평가", 응용통계연구, 24(1), pp.161~167 (2011), 한국통계학회
- Kenward MG, "The use of baseline covariates studies", Biostatistics, 11(1), pp.1~17 (2010)[DOI]
- Yan Z, "The impact of baseline covariates on the efficiency of statistical analyses of crossover designs", Stat Med, 32(6), pp.956~963 (2013)[DOI]
- Mehrotra DV, "A recommended analyses for 2<TEX>$\times$<", TEX>2 crossover trials with baseline measurements, 2014, pp.13(6), 376~387